Advertisement

Topics

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

20:58 EDT 16 Apr 2018 | SCRIP

Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase...

      

Related Stories

 

Original Article: Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

NEXT ARTICLE

More From BioPortfolio on "Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...